Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Gastroesophageal reflux disease (GERD) - erosive esophagitis healing and maintenance, symptomatic GERD.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Part of dual or triple therapy for *Helicobacter pylori* eradication.
## Adult Dosing
* **Erosive Esophagitis:** 40 mg orally once daily for 4-8 weeks. May increase to 40 mg twice daily in severe cases. For maintenance, 40 mg orally once daily.
* **Symptomatic GERD:** 20-40 mg orally once daily.
* **Hypersecretory Conditions:** Starting dose 40 mg orally twice daily. Doses up to 240 mg daily have been used, divided into two doses.
* ***H. pylori* Eradication:** 40 mg orally twice daily in combination with antibiotics.
## Pediatric Dosing
* **Erosive Esophagitis (GERD-associated):**
* **1 to 5 years:** 20 mg orally once daily for 8 weeks.
* **5 to 12 years:** 20-40 mg orally once daily for 8 weeks.
* **12 to 17 years:** 40 mg orally once daily for 8 weeks.
## Dose Adjustments
No specific dose adjustments are typically needed for hepatic impairment, though caution is advised. In severe hepatic impairment, consider reducing the dose to 20 mg once daily. No dose adjustment is necessary for renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
* **Serious:** *Clostridium difficile*-associated diarrhea, bone fracture (hip, wrist, spine) with prolonged use, hypomagnesemia (especially with concomitant diuretic use), vitamin B12 deficiency, systemic lupus erythematosus (cutaneous and systemic).
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, and certain HIV protease inhibitors (e.g., atazanavir, nelfinavir) may have decreased absorption. Separate administration by at least 2 hours.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Monitor methotrexate levels and consider dose reduction or interruption of pantoprazole.
* **CYP2C19 substrates:** Pantoprazole is a weak inhibitor of CYP2C19. Monitor for potential interactions with drugs metabolized by this enzyme (e.g., clopidogrel, although clinical significance is debated).
## Monitoring
* Monitor for signs and symptoms of *C. difficile*-associated diarrhea.
* Consider periodic monitoring of serum magnesium levels in patients on long-term therapy, especially those on diuretics.
* Assess for signs of vitamin B12 deficiency with prolonged use.
* Monitor for bone pain or fracture risk factors.
## Clinical Pearls
* Pantoprazole is available in delayed-release tablets and as an intravenous formulation.
* Administer delayed-release tablets at least 1 hour before a meal.
* Long-term use of PPIs is associated with increased risk of fractures, *C. difficile* infection, and hypomagnesemia. Use the lowest effective dose for the shortest duration necessary.
* IV formulation should be administered as a slow infusion over 15 minutes.
***
**Disclaimer:** This information is intended for educational purposes and does not replace the need to consult current prescribing information, guidelines, and physician orders. Dosing and safety considerations may vary based on individual patient factors and institutional protocols.
